Theme stage · accelerating
Gene therapy and rare-disease stocks to watch.
As of 15 November 2026
Research view: more likely to lead the S&P 500. Xeris Biopharma's shares are modestly more likely than not to beat the S&P 500 over three months because Recorlev sales rose 93% to $71.5 million in the third quarter and 2026 revenue guidance rose to $395–405 million.
Research view: more likely to lead the S&P 500. Liquidia Corporation's shares are modestly more likely to beat the S&P 500 because YUTREPIA sales rose 31% to $222.7 million in the third quarter with record October shipments; preliminary fourth-quarter sales, due in early January 2027, show whether that holds as PH-ILD use winds down.
Research view: more likely to lead the S&P 500. Viridian Therapeutics' shares are modestly more likely than not to beat the S&P 500: Lumvoa's $24.7 million first full quarter beat estimates and VRDN-008 data on 9 November 2026 added an autoimmune program.
Disc Medicine's shares are modestly favoured to beat the S&P 500 over three months because bitopertin passed its Phase 3 APOLLO trial on 19 October 2026, answering the FDA's February rejection.
Research view: more likely to lead the S&P 500. Eton Pharmaceuticals is modestly more likely than not to beat the S&P 500 over three months, after third-quarter revenue of $57.9 million, up 158%, lifted its 2026 guide above $175 million.
“3 months” is the stock's market price change over the last three months, not a FrontierPicks return. The "3 months" column is the stock's 3-month price move, one of the three inputs to that score, weighted 20% — not the ranking itself, so rows do not descend in it.
How this page is built
These are the names FrontierPicks researches in the gene therapy and rare-disease stocks theme, each with a dated research note. Names in the latest top-50 momentum scan come first, ordered by a composite momentum score — 1-month price trend 50%, 3-month trend 20% and acceleration 30% — computed arithmetically from daily closing prices, through the last completed session; the rest follow by the research's conviction, highest first. The research decides which stocks belong to each theme; this one currently reads as accelerating: attention and buyers are arriving.
Questions
- What gene therapy and rare-disease stocks does FrontierPicks cover?
- As of 15 November 2026, the gene therapy and rare-disease stocks FrontierPicks researches are led by XERS, LQDA, VRDN, IRON, each with a dated research note. Names in the latest top-50 momentum scan come first, ordered by composite momentum score; the rest follow by the research's conviction, highest first.
- Is the gene therapy and rare-disease stocks theme accelerating or slowing?
- FrontierPicks reads this theme as accelerating (attention and buyers are arriving) as of 15 November 2026. Rare-disease drug developers are drawing fresh trial data, new analyst coverage and new capital. Viridian (VRDN) rallied on positive VRDN-008 results on 9 November 2026, Guggenheim started coverage of Disc Medicine (IRON) at Buy with a $132 target the same day, and PepGen (PEPG) priced a $125 million offering at $5.00 a share on 12 November 2026. Analysts are still raising targets after the moves: Guggenheim lifted its PepGen target to $15 from $7, and BTIG lifted its Liquidia (LQDA) target to $87. Liquidia joined the group after Raymond James, Needham, BTIG and HC Wainwright raised or set targets between 11 November 2026 and 13 November 2026.
- How does FrontierPicks rank gene therapy and rare-disease stocks?
- Names in the latest top-50 momentum scan come first, ordered by composite momentum score; the rest follow by the research's conviction, highest first. The full method is on the methodology page.
Related
As of 15 November 2026